Phase III MATRix Trial Results Published in The Lancet, Establishing New Standard for Primary CNS Lymphoma

The results of the IELSG43/MATRix randomized Phase III trial in primary central nervous system lymphoma (PCNSL) have been published in The Lancet. The study, the largest randomized trial in untreated PCNSL to date, demonstrated that high-dose chemotherapy followed by autologous stem-cell transplantation significantly improves progression-free and overall survival, establishing it as the preferred consolidation strategy for fit patients.